|
Protocol Number:
07-C-0100
- Title:
Collection of Blood from Patients with Prostate Cancer
- Number:
07-C-0100
- Summary:
Background:
-It is not fully understood why prostate cancer in some men becomes androgen-independent (no longer responds to anti-androgen medication), but genetics likely plays an important role.
-Genes contain the hereditary information that is passed down from parents to children. Although everyone has the same set of genes, individuals can have different forms of the same gene.
-Differences in genes may explain, at least in part, why some people develop a more aggressive form of prostate cancer than others.
Objectives:
-To obtain blood samples from patients with prostate cancer to try to identify gene differences associated with progression to the androgen independent state.
Eligibility:
-All patients participating in NCI prostate cancer protocols.
Design:
-Patients with prostate cancer are evaluated in the NCI's Medical Oncology Clinic.
-Blood samples are collected at the initial visit or at follow-up visits.
-DNA (genetic material) and white blood cells are extracted from these samples to be used for genotyping and establishment of cell lines.
-Gene variations are correlated with prostate cancer prognosis and prognostic indicators.
- Sponsoring Institute:
-
National Cancer Institute (NCI)
- Recruitment Detail
- Type:
Participants currently recruited/enrolled
- Gender:
Male
- Referral Letter Required:
No
- Population Exclusion(s):
Female
Children
- Eligibility Criteria:
INCLUSION CRITERIA:
Patients 18 years of age and older are eligible.
Patients with a diagnosis of prostate cancer are eligible.
EXCLUSION CRITERIA:
Children are not eligible.
- Special Instructions:
Currently Not Provided
- Keywords:
-
Hormone-Refractory
-
Bone Metastases
-
Genome Analysis
-
Androgen Independent
-
Tissue
-
Genotyping
- Recruitment Keyword(s):
-
Prostate Cancer
- Condition(s):
-
Prostate Cancer
- Investigational Drug(s):
- None
- Investigational Device(s):
- None
- Intervention(s):
- None
- Supporting Site:
- National Cancer Institute
- Contact(s):
-
NCI Referral Office
National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: NCI Clinical Trials Referral Office Phone: 1-888-NCI-1937 Fax: Not Listed Electronic Address: ncicssc@mail.nih.gov
- Citation(s):
-
Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM Jr, Bueschen AJ, Lowe BA. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998 Oct 8;339(15):1036-42.
-
Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol. 1985 Jun;3(6):827-41.
-
Ruijter E, van de Kaa C, Miller G, Ruiter D, Debruyne F, Schalken J. Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev. 1999 Feb;20(1):22-45. Review. No abstract available.
If you have:
Search The Studies | Help | Questions | Clinical Center Home | NIH Home
National Institutes of Health Clinical Center
Bethesda, Maryland 20892. Last update: 05/05/2009
|
|